Gut bacteria with infliximab for Crohn's disease healing
Treatments studied
Part of Digestive system clinical trials.
This study tests whether adding a specific gut bacteria (Akkermansia muciniphila) to the standard Crohn's treatment infliximab helps heal the intestinal lining better. This could improve long-term control of Crohn's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of Crohn's disease.
- Your Crohn's disease is currently active (moderate symptoms).
- You have not used biologic medications (like infliximab, adalimumab, ustekinumab, or vedolizumab) in the past 8 weeks.
- You have not taken antibiotics or probiotics in the past 4 weeks.
- You have never had surgery on your intestines related to Crohn's disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining infliximab (a biologic medicine that reduces inflammation) with azathioprine (an immune-suppressing drug) is safe and effective for children with moderate to severe Crohn's disease who haven't tried these medicines before.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
This study tests whether adding a natural fatty acid (palmitoleic acid) to a standard Crohn's treatment (infliximab) is better at healing the lining of the intestine. It aims to see if this combination can calm the disease and reduce symptoms.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new Crohn's Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.